TY - JOUR
T1 - Third-line trabectedin for a metastatic desmoplastic small round cell tumour treated with multimodal therapy
AU - Brunetti, Anna Elisabetta
AU - Delcuratolo, Sabina
AU - Lorusso, Vito
AU - Palermo, Loredana
AU - Di Giorgio, Angelo
AU - Pisconti, Salvatore
AU - Silvestris, Nicola
PY - 2014/7/1
Y1 - 2014/7/1
N2 - Background: Desmoplastic small round cell tumour (DSRCT) is a rare and aggressive cancer that usually develops in the peritoneal cavity of young males. Its prognosis is dismal, with current treatment options including the combination of multi-agent chemotherapy, aggressive surgery, radiation therapy, and autologous stem cell transplantation. Hyperthermic intraperitoneal chemotherapy (HIPEC) may also be an option. Case Report: Herein we report the administration of the marine-derived multi-target antineoplastic agent, trabectedin, in a patient with DSRCT, heavily pre-treated with conventional multi-agent chemotherapy, HIPEC, and surgery. Results: The patient achieved a prolonged partial response and an extended period of stable disease with third-line trabectedin, following disease progression after conventional multi-agent chemotherapy, HIPEC, and surgery. Conclusion: Trabectedin may be a treatment option in multimodal therapy for the management of DSRCT and warrants further research to explore the impact of trabectedin in the treatment of this disease.
AB - Background: Desmoplastic small round cell tumour (DSRCT) is a rare and aggressive cancer that usually develops in the peritoneal cavity of young males. Its prognosis is dismal, with current treatment options including the combination of multi-agent chemotherapy, aggressive surgery, radiation therapy, and autologous stem cell transplantation. Hyperthermic intraperitoneal chemotherapy (HIPEC) may also be an option. Case Report: Herein we report the administration of the marine-derived multi-target antineoplastic agent, trabectedin, in a patient with DSRCT, heavily pre-treated with conventional multi-agent chemotherapy, HIPEC, and surgery. Results: The patient achieved a prolonged partial response and an extended period of stable disease with third-line trabectedin, following disease progression after conventional multi-agent chemotherapy, HIPEC, and surgery. Conclusion: Trabectedin may be a treatment option in multimodal therapy for the management of DSRCT and warrants further research to explore the impact of trabectedin in the treatment of this disease.
KW - Chemotherapy
KW - Desmoplastic small round cell tumour
KW - Multimodal therapy
KW - Trabectedin
UR - http://www.scopus.com/inward/record.url?scp=84906315815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906315815&partnerID=8YFLogxK
M3 - Article
C2 - 24982387
AN - SCOPUS:84906315815
VL - 34
SP - 3683
EP - 3688
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 7
ER -